Eden vs NexLife (2026): prices, structure, verdict

On tirzepatide, NexLife↗ is cheaper: $215 versus $408 a month all-in — a $193 monthly gap, $2,316 across a year of maintenance dosing, and NexLife's figure is dose-flat while Eden's structure is not.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, NexLife is cheaper: $165 versus $198 a month all-in — a $33 monthly gap, $396 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Eden: the record, condensed

On tirzepatide, the number that matters at Eden is $408 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Pricing steps with the dose here: from $348 at entry to $408 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $720 a year, which is why every ranking on this site uses the larger number.

Inside that $408 sits a mandatory $99-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $309, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #16 of 17 in the verified tirzepatide index — $193/month above the floor (NexLife, $215) — and sits $41 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,896.

Eden’s semaglutide program bills $198 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

A required $99/month membership is part of the deal, and part of the figure above: $99 of medication plus $99 of platform equals the $198 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #10 of 20 verified programs, with the floor $65/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $151 a month. A year at this figure: $2,376 monthly-billed.

Operationally at Eden: shipping included; commitment membership auto-renews; cancellation membership auto-renews until cancelled; pharmacy not publicly named — ask in writing before paying; states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Eden page · visit Eden ↗

NexLife: the record, condensed

Start with the load-bearing figure: $215 a month, all-in, is what NexLife charges for tirzepatide at the 10 mg basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $215 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Commitment buys a discount here, term by term: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic tirzepatide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #1 of 17 in the verified tirzepatide index — the floor of the market itself — and sits $234 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $2,580, or $2,232 on the prepaid path.

On semaglutide, the number that matters at NexLife is $165 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $165 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for semaglutide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

To place the number: #5 of 20 verified programs, with the floor $32/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $184 a month. A year at this figure: $1,980 monthly-billed ($1,740 prepaid).

Operationally at NexLife: shipping free expedited shipping included; commitment none on monthly; cancellation cancel any time on monthly; pharmacy named (6 named partner pharmacies); states: 50 states published; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NexLife page · visit NexLife ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $215 (NexLife) against $408 (Eden). $193 a month sounds survivable; $2,316 a year is a decision.

Structure sharpens the gap: NexLife’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while Eden’s is not — so NexLife’s number is a ceiling and Eden’s advertised entry ($348) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Eden’s total includes a mandatory $99/month membership; NexLife has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: NexLife at $165, Eden at $198 — a $33 monthly spread that compounds to $396 over a maintenance year and $792 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $33 gap is exactly what it appears to be.

Eden’s total includes a mandatory $99/month membership; NexLife has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $193/month spread into medication: $2,316 a year equals roughly 10.8 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Eden $408/mo month-to-month versus NexLife $186/mo on the labeled 12-month plan ($2,232 upfront; $215 month-to-month). Same winner on both bases — NexLife leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Eden $1,224 monthly; NexLife $645 monthly (or $585 prepaid) — best path favors NexLife by $639. 6 months: Eden $2,448 monthly; NexLife $1,290 monthly (or $1,140 prepaid) — best path favors NexLife by $1,308. 12 months: Eden $4,896 monthly; NexLife $2,580 monthly (or $2,232 prepaid) — best path favors NexLife by $2,664. 24 months: Eden $9,792 monthly; NexLife $5,160 monthly (or $4,464 prepaid) — best path favors NexLife by $5,328.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Eden $594 vs NexLife $447 (prepaid) — $147 to NexLife. 6 mo: Eden $1,188 vs NexLife $882 (prepaid) — $306 to NexLife. 12 mo: Eden $2,376 vs NexLife $1,740 (prepaid) — $636 to NexLife. 24 mo: Eden $4,752 vs NexLife $3,480 (prepaid) — $1,272 to NexLife.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Eden publishes “most states”; NexLife publishes “50 states published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: NexLife names its network (6 named partner pharmacies); Eden does not, which shifts the burden of verification onto your intake questions.

Exit terms: Eden — membership auto-renews; membership auto-renews until cancelled. NexLife — none on monthly; cancel any time on monthly.

Evidence: Eden source-verified (captured 2026-08-05); NexLife source-verified (2026-08-10).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #16 and #1 of 17: between them lie 14 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #10 and #5 of 20: between them lie 4 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Eden and NexLife

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Eden: membership auto-renews until cancelled; NexLife: cancel any time on monthly) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings